James E. Crowe

Last updated
James E. Crowe Jr.
Born (1961-08-14) August 14, 1961 (age 61)
Nashville, Tennessee
NationalityAmerican
Awards2020 Golden Goose Award
Academic background
Academic advisors Robert Chanock, Brian R. Murphy

James Earl Crowe Jr. (born August 14, 1961) is an American immunologist and pediatrician as well as Professor of Pediatrics and Pathology, Microbiology, and Immunology at Vanderbilt University Medical Center. [1]

Contents

Education and career

James Crowe was born August 14, 1961, in Nashville, Tennessee. [2] He received his B.S. from Davidson College in 1983. [2] Then went on to medical school at the University of North Carolina, Chapel Hill, completing his M.D. in 1987. [1] [2] He continued at the University of North Carolina for his pediatric internship and residency from 1987 to 1990. [2] Following his medical training, Crowe moved to the U.S. National Institutes of Health in 1990 serving first as a Medical Staff Fellow from 1990 to 1993 under Robert Chanock and Brian R. Murphy, then as a Senior Research Investigator in the Laboratoy of Infectious Diseases from 1993 to 1995. [2] He then completed a clinical fellowship in pediatric infectious diseases at Vanderbilt Medical Center before being appointed to the faculty as an assistant professor in the Department of Pediatrics in 1996. [2] Crowe was subsequently promoted to associate professor in 2001, and to full professor in the Department of Pediatrics in 2004. [2] He is currently in Ann Scott Carell Chair at the Vanderbilt University Medical Center, an endowed professorship as well as Director of the Vanderbilt Vaccine Center. [2] In 2014, Crowe was elected to the National Academy of Medicine. [2]

Research

James Crowe's research has focused on adaptive immune responses to various viral pathogens, in particular influenza virus, HIV, dengue virus, respiratory syncytial virus, rotavirus, human metapneumovirus and vaccinia virus. His group is particularly known for their work on antibody recognition of viral pathogens [3] and for its identification and sequencing of monoclonal antibodies against SARS-CoV-2 from survivors of COVID-19 in Wuhan, China. [4]

Notable publications

Awards and honors

In 2020, Crowe received a Golden Goose Award for excellence in federally funded research. [4]

Related Research Articles

<span class="mw-page-title-main">Infection</span> Invasion of an organisms body by pathogenic agents

An infection is the invasion of tissues by pathogens, their multiplication, and the reaction of host tissues to the infectious agent and the toxins they produce. An infectious disease, also known as a transmissible disease or communicable disease, is an illness resulting from an infection.

<span class="mw-page-title-main">Rhinovirus</span> Genus of viruses (Enterovirus)

The rhinovirus is the most common viral infectious agent in humans and is the predominant cause of the common cold. Rhinovirus infection proliferates in temperatures of 33–35 °C (91–95 °F), the temperatures found in the nose. Rhinoviruses belong to the genus Enterovirus in the family Picornaviridae.

<span class="mw-page-title-main">Respiratory syncytial virus</span> Species of a virus

Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a common, contagious virus that causes infections of the respiratory tract. It is a negative-sense, single-stranded RNA virus. Its name is derived from the large cells known as syncytia that form when infected cells fuse.

<i>Human metapneumovirus</i> Species of virus

Human metapneumovirus is a negative-sense single-stranded RNA virus of the family Pneumoviridae and is closely related to the Avian metapneumovirus (AMPV) subgroup C. It was isolated for the first time in 2001 in the Netherlands by using the RAP-PCR technique for identification of unknown viruses growing in cultured cells. It is the second most common cause after respiratory syncytial virus (RSV) of lower respiratory infection in young children.

Avian infectious bronchitis (IB) is an acute and highly contagious respiratory disease of chickens. The disease is caused by avian infectious bronchitis virus (IBV), a coronavirus, and characterized by respiratory signs including gasping, coughing, sneezing, tracheal rales, and nasal discharge. In young chickens, severe respiratory distress may occur. In layers, respiratory distress, nephritis, decrease in egg production, and loss of internal and external egg quality are reported.

Viral pneumonia is a pneumonia caused by a virus. Pneumonia is an infection that causes inflammation in one or both of the lungs. The pulmonary alveoli fill with fluid or pus making it difficult to breathe. Pneumonia can be caused by bacteria, viruses, fungi or parasites. Viruses are the most common cause of pneumonia in children, while in adults bacteria are a more common cause.

An emergent virus is a virus that is either newly appeared, notably increasing in incidence/geographic range or has the potential to increase in the near future. Emergent viruses are a leading cause of emerging infectious diseases and raise public health challenges globally, given their potential to cause outbreaks of disease which can lead to epidemics and pandemics. As well as causing disease, emergent viruses can also have severe economic implications. Recent examples include the SARS-related coronaviruses, which have caused the 2002-2004 outbreak of SARS (SARS-CoV-1) and the 2019–21 pandemic of COVID-19 (SARS-CoV-2). Other examples include the human immunodeficiency virus which causes HIV/AIDS; the viruses responsible for Ebola; the H5N1 influenza virus responsible for avian flu; and H1N1/09, which caused the 2009 swine flu pandemic. Viral emergence in humans is often a consequence of zoonosis, which involves a cross-species jump of a viral disease into humans from other animals. As zoonotic viruses exist in animal reservoirs, they are much more difficult to eradicate and can therefore establish persistent infections in human populations.

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.

<span class="mw-page-title-main">Antibody-dependent enhancement</span> Antibodies rarely making an infection worse instead of better

Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication. The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease, but is not limited to respiratory disease. It has been observed in HIV, RSV virus and Dengue virus and is monitored for in vaccine development.

<span class="mw-page-title-main">Influenza</span> Infectious disease, often just "the flu"

Influenza, commonly known as "the flu", is an infectious disease caused by influenza viruses. Symptoms range from mild to severe and often include fever, runny nose, sore throat, muscle pain, headache, coughing, and fatigue. These symptoms begin from one to four days after exposure to the virus and last for about 2–8 days. Diarrhea and vomiting can occur, particularly in children. Influenza may progress to pneumonia, which can be caused by the virus or by a subsequent bacterial infection. Other complications of infection include acute respiratory distress syndrome, meningitis, encephalitis, and worsening of pre-existing health problems such as asthma and cardiovascular disease.

<span class="mw-page-title-main">Vaccine Research Center</span>

The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.

A neutralizing antibody (NAb) is an antibody that defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically. Neutralization renders the particle no longer infectious or pathogenic. Neutralizing antibodies are part of the humoral response of the adaptive immune system against viruses, intracellular bacteria and microbial toxin. By binding specifically to surface structures (antigen) on an infectious particle, neutralizing antibodies prevent the particle from interacting with its host cells it might infect and destroy.

<span class="mw-page-title-main">Monroe Carell Jr. Children's Hospital at Vanderbilt</span> Hospital in Tennessee, United States

Monroe Carell Jr. Children's Hospital at Vanderbilt, also known as Children's Hospital at Vanderbilt, is a nationally ranked pediatric acute care children's teaching hospital and entity of Vanderbilt University Medical Center in Nashville, Tennessee. The hospital is affiliated with Vanderbilt University School of Medicine's Department of Pediatrics.

<span class="mw-page-title-main">Mel Krajden</span>

Mel Krajden is a physician and professor of Pathology and Laboratory Medicine at the University of British Columbia in Vancouver, British Columbia, Canada. He is the medical director of the BCCDC Public Health Laboratory. Dr. Krajden obtained his BSc, MD, and FRCPC at McGill University, followed by a fellowship in Infectious Diseases at Stanford University. He is also the medical director of the Public Health Laboratory at the British Columbia Centre for Disease Control. His research focuses on the prevention and care of hepatitis, human papillomavirus, and human immunodeficiency virus.

Larry J. Anderson is an American virologist who served in leadership positions at the Centers for Disease Control and Prevention (CDC) for more than three decades. He was director of the Division of Viral Diseases in the National Center for Immunization and Respiratory Diseases at the CDC (2006–2010), and chief of the Respiratory and Enteric Viruses Branch of the CDC Division of Viral and Rickettsial Diseases (1982–2006). From 2003 to 2006, Anderson led the CDC’s Post-Outbreak SARS Program, and he served as a special advisor on smallpox in the Office of the Associate Director for Terrorism, Preparedness, and Response.

<span class="mw-page-title-main">Brian R. Murphy</span>

Brian R. Murphy is an American virologist and former co-chief of the Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Disease.

<span class="mw-page-title-main">Kizzmekia Corbett</span> American immunologist

Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is an Assistant Professor of Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health and the Shutzer Assistant Professor at the Harvard Radcliffe Institute since June 2021.

<span class="mw-page-title-main">Convalescent plasma</span> Blood plasma from disease survivor

Convalescent plasma is the blood plasma collected from a survivor of an infectious disease. This plasma contains antibodies specific to a pathogen and can be used therapeutically by providing passive immunity when transfusing it to a newly infected patient with the same condition. Convalescent plasma can be transfused as it has been collected or become the source material for the hyperimmune serum which consists largely of IgG but also includes IgA and IgM. or as source material for anti-pathogen monoclonal antibodies, Collection is typically achieved by apheresis, but in low-to-middle income countries, the treatment can be administered as convalescent whole blood.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.

Anne Moscona is an American virologist and pediatrician. She is best known for identifying cell entry mechanisms for enveloped respiratory viruses, elucidating general infection mechanisms that apply to parainfluenza virus, Nipah virus, measles virus, and other viruses, and for applying this knowledge to identify antiviral strategies to prevent infection by viruses including SARS-CoV-2. She is frequently consulted as a medical expert during viral outbreaks, including epidemic and pandemic influenza. Since 2016, she has served as the Sherie L. Morrison Professor Microbiology & Immunology, Professor of Pediatrics, and Professor of Physiology & Cellular Biophysics at Columbia University Medical Center in New York City, where she directs the Center for Host Pathogen Interaction. In 2022, Moscona was elected as president of the American Society for Virology, the nation's leading virology research organization, and will lead the organization starting in July 2023. For the last two years she has served the American Society for Virology as Councilor for Medical Virology.

References

  1. 1 2 "James Crowe, MD". Vanderbilt University. Retrieved 12 July 2019.
  2. 1 2 3 4 5 6 7 8 9 "Curriculum Vitae; April 5 2017" (PDF). Vanderbilt University. Retrieved 12 July 2019.
  3. "James E. Crowe, Jr., MD". American Society for Clinical Investigation. Retrieved 12 July 2019.
  4. 1 2 Asbury, Meredith (December 2020). "2020: The Human Immunome: Small Moves Become a Movement". The Golden Goose Award. American Association for the Advancement of Science . Retrieved 23 March 2023.